About nextcure inc - NXTC
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
NXTC At a Glance
NextCure, Inc.
9000 Virginia Manor Road
Beltsville, Maryland 20705
| Phone | 1-240-399-4900 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -55,844,000.00 | |
| Sector | Health Technology | Employees | 40 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
NXTC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.424 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.066 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 1.404 |
NXTC Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,396,100.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
NXTC Liquidity
| Current Ratio | 4.14 |
| Quick Ratio | 4.14 |
| Cash Ratio | 3.958 |
NXTC Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -83.973 |
| Return on Equity | -111.226 |
| Return on Total Capital | -139.276 |
| Return on Invested Capital | -101.797 |
NXTC Capital Structure
| Total Debt to Total Equity | 14.747 |
| Total Debt to Total Capital | 12.852 |
| Total Debt to Total Assets | 10.088 |
| Long-Term Debt to Equity | 11.871 |
| Long-Term Debt to Total Capital | 10.345 |